Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7157902 | 0.94 | L3MBTL1 (0.41) | L3MBTL1LMNATDP1CYP2C19HIF1A | |
| SCHEMBL6955217 | 0.90 | LMNA (0.42) | L3MBTL1LMNATDP1CYP2C19HIF1A | |
| SCHEMBL1870865 | 0.88 | GAA (0.32) | L3MBTL1LMNAGAA | |
| SCHEMBL374291 | 0.84 | LMNA (0.46) | L3MBTL1LMNATDP1CYP2C19HIF1A | |
| SCHEMBL4444063 | 0.82 | SLC6A3 (0.33) | — | |
| SCHEMBL15604555 | 0.79 | NOS2 (0.36) | L3MBTL1LMNAGAA | |
| SCHEMBL17255899 | 0.77 | LMNA (0.46) | L3MBTL1LMNATDP1CYP2C19HIF1A | |
| SCHEMBL4650446 | 0.77 | LMNA (0.46) | L3MBTL1LMNATDP1CYP2C19HIF1A | |
| SCHEMBL21794157 | 0.77 | — | — | |
| SCHEMBL6436844 | 0.77 | LMNA (0.46) | L3MBTL1LMNATDP1CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101309900-B | Substituted cycloalkene derivative | DAIICHI SANKYO CO LTD | 2015-04-22 | — | — | CN | disclosed |
| US-RE43858-E1 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-7935835-B2 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1935879-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | CD40, LITAF, TNF | L3MBTL1 418/4885LMNA 1566/4885TDP1 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.